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Aims The in situ release and maintaining of cells to promote revascularization is a new goal of 
cardiovascular therapy. Endothelial progenitor cells (EPC) may contribute to the process of vascular 
repair. Medical devices realized according to tissue engineering are composed by a cellular 
component and by an artificial component, usually made of a biocompatible polymer. Scaffolds 
may be coated with bio-polymers like fibrin to enhance cell adhesion and growth. 
Aim of this study was to realize nanocomposite 3D scaffolds composed by a synthetic polymer 
coated with fibrin to support EPC growth and to promote in vivo angiogenesis. 
Methods 3D PEtU-PDMS scaffolds were studied in vitro for their biocompatibility (viability and 
proliferation tests; citokine release). In vivo biocompatibility was studied by intramuscular implant 
in a rabbit model. The scaffolds were fabricated by spray-phase inversion technique. 25U/mL 
thrombin was sprayed during the fabrication process. The composite scaffold was then incubated 
o.n. at 37°C with 18mg/mL fibrinogen. The scaffold morphology was analysed by stereo-
microscopy and by scanning electron microscopy (SEM).  
EPC obtained from peripheral blood were cultured for 1 week on the scaffolds at the concentration 
of 1x106 cell/ml. Fibronectin coating was used as a control. Cell viability was assessed by confocal 
laser (Calcein-AM incorporation).  
To test in vivo angiogenesis, EPC-seeded scaffolds were subcutaneously implanted into the back of 
rats for 14 days. After harvesting, the scaffolds were examined histologically and 
immunohistochemically to evaluate inflammatory response and neovascularization. 
Results In vitro and in vivo biocompatibility data demonstrated absence of any citotoxic effect, 
immunocompatibility and a slight inflammatory reaction without any sign of encapsulation and 
implant rejection. Morphological analyses showed an homogeneus fibrin coating of the scaffolds, 
tightly bound and interconnected to the PEtU-PDMS surface. SEM showed the presence of a well 
organized layer of fibres in a nm scale (mean diameter ~140nm). Cell viability and phenotype were 
not affected when EPC were seeded on PEtU-PDMS/fibrin scaffolds. The histological observation 
of explanted scaffolds revealed a slightly inflammatory response and a significant increased 
numbers of neovessels in tissues surrounding the EPC-seeded scaffold as compared to the scaffold 
without cells. 
Conclusions Our data suggest that PEtU-PDMS/fibrin scaffold obtained with a new spray 
manufacturing technology can support in vitro EPC growth and promote in vivo neovascularisation. 
Further studies are currently under way in an ischemic hindlimb rat model. 
 
 
 
